Kineta Unveils New Preclinical Data on its Anti-CD27 Agonist Lead Antibodies at AACR 2022 Seattle, WA — (April 13, 2022) Kineta, Inc., a clinical stage biotechnology company focused on the developmen ...

Kineta to Present Poster on Anti-CD27 Agonist Antibody Program at the AACR Annual Meeting 2022 Seattle, WA — (March 21, 2022) Kineta, Inc., a clinical stage biotechnology company focused on the devel ...

Kineta Invited to Participate in the Cowen 42nd Annual Health Care Virtual Conference Seattle, WA — (February 24, 2021) Kineta, Inc., a clinical stage biotechnology company focused on the developmen ...

Seattle, WA — (January 24, 2022) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today an upcoming presentation at the 6 ...

Kineta to Present at the H.C. Wainwright Bioconnect Virtual Conference Seattle, WA — (January 11 , 2022) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immun ...

Kineta Presented New Preclinical Data on its Anti-CD27 Agonist Antibody Program at the ESMO Immuno-oncology Congress 2021 Seattle, WA — (December 17, 2021) Kineta, Inc., a clinical stage biotechnolog ...

Kineta Presents Phase 1/2 Clinical Trial Design of KVA12.1 at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting Anti-VISTA immunotherapy is being advanced in a range of solid tumors ...

Kineta Presented Compelling Preclinical Data on its New CD27 Antibody Program at the 2021 SITC Annual Meeting Seattle, WA — (November 16, 2021) Kineta, Inc., a clinical stage biotechnology company fo ...

Kineta Presents Preclinical Data on its New CD27 Program at the AACR Conference on Tumor Immunology and Immunotherapy Kineta expands the company’s immuno-oncology pipeline with the addition of a new ...

Kineta Announces Poster Presentation at the 2021 American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy Seattle, WA — (September 28, 2021) Kineta, Inc., a clinical ...